Nancy Lurker interview on future of Interpace Diagnostics




very little of what she said actually panned out.
I just think back to how poorly Thyramir was launched. She set an arbitrary date based on little experience and overall ignorance of the process of launching a diagnostic test, but we were able to say we launched it on the date she said we would.

Minus the study being published
without the ability to leave behind any literature or information
no reimbursement details


We have a better test than anything else on the market, but you only get one chance to launch and we blew it. When CBLpath publishes their data we are toast because we didn't build a big enough base of business in the nine months we've been selling this stuff.
 


Summary:
Pancragen is dead in the water.
Thyramir is an accident waiting to happen. Can't even get licensing in New York State!!!!
But wait! there's more - just wait until all accounts receive 30% price increase in roster bills. ......
 



Write your reply...